These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 27811198

  • 1. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
    AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N.
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
    [Abstract] [Full Text] [Related]

  • 2. Edoxaban: A direct oral anticoagulant.
    Poulakos M, Walker JN, Baig U, David T.
    Am J Health Syst Pharm; 2017 Feb 01; 74(3):117-129. PubMed ID: 28122753
    [Abstract] [Full Text] [Related]

  • 3. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI.
    Thromb Haemost; 2010 Sep 01; 104(3):642-9. PubMed ID: 20589317
    [Abstract] [Full Text] [Related]

  • 4. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV, O'Callaghan JM, Handa A.
    Vasc Health Risk Manag; 2016 Sep 01; 12():329-35. PubMed ID: 27563246
    [Abstract] [Full Text] [Related]

  • 5. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
    Barrios V, Escobar C.
    Expert Rev Cardiovasc Ther; 2015 Sep 01; 13(7):811-24. PubMed ID: 26068539
    [Abstract] [Full Text] [Related]

  • 6. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Di Nisio M, van Es N, Carrier M, Wang TF, Garcia D, Segers A, Weitz J, Buller H, Raskob G.
    J Thromb Haemost; 2019 Nov 01; 17(11):1866-1874. PubMed ID: 31271705
    [Abstract] [Full Text] [Related]

  • 7. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE.
    Thromb Haemost; 2018 Aug 01; 118(8):1439-1449. PubMed ID: 30060256
    [Abstract] [Full Text] [Related]

  • 8. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM.
    Lancet; 2015 Jun 06; 385(9984):2288-95. PubMed ID: 25769361
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, Ibusuki K, Ushida H, Abe K, Tachibana S.
    Thromb Res; 2014 Dec 06; 134(6):1198-204. PubMed ID: 25294589
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
    Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Kiuchi Y, Abe K, Tachibana S.
    Thromb Res; 2014 Jun 06; 133(6):1016-22. PubMed ID: 24680549
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF, Ganetsky V, Spinler SA.
    Clin Ther; 2013 Jan 06; 35(1):4-27. PubMed ID: 23328267
    [Abstract] [Full Text] [Related]

  • 13. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
    Kuroda Y, Hirayama C, Hotoda H, Nishikawa Y, Nishiwaki A.
    Vasc Health Risk Manag; 2013 Jan 06; 9():593-8. PubMed ID: 24124376
    [Abstract] [Full Text] [Related]

  • 14. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y, Kamisato C, Honda Y.
    Eur J Pharmacol; 2014 Nov 05; 742():15-21. PubMed ID: 25179572
    [Abstract] [Full Text] [Related]

  • 15. Establishing Edoxaban's Role in Anticoagulation.
    Guirguis E, Brown D, Grace Y, Patel D, Henningfield S.
    J Pharm Pract; 2016 Jun 05; 29(3):228-38. PubMed ID: 27169733
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Edoxaban: an update on the new oral direct factor Xa inhibitor.
    Bounameaux H, Camm AJ.
    Drugs; 2014 Jul 05; 74(11):1209-31. PubMed ID: 25034361
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C, Tellor KB, Armbruster AL.
    Ann Pharmacother; 2015 Jul 05; 49(7):843-50. PubMed ID: 25855704
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation　- The Prospective KYU-RABLE Study.
    Takahashi N, Mukai Y, Kimura T, Yamaguchi K, Matsumoto T, Origasa H, Okumura K, KYU-RABLE Investigators.
    Circ J; 2019 Sep 25; 83(10):2017-2024. PubMed ID: 31511436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.